Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin

Area of Science:

• Oncology
• Cancer Stem Cell Biology
• Pharmacology

Background:

• Prostate cancer stem cells (PrCSCs) exhibit stemness properties, driving tumor growth, metastasis, and therapy resistance.
• Napabucasin (BBI608) is a small molecule known to suppress stemness-high cancer cells in various cancers.
• The specific effects of napabucasin on prostate cancer cells and PrCSCs remain largely undefined.

Purpose of the Study:

• To investigate the efficacy of napabucasin in targeting prostate cancer stem cells (PrCSCs).
• To evaluate napabucasin's impact on prostate cancer cell proliferation, migration, colony formation, and apoptosis in vitro.
• To assess napabucasin's effects on PrCSC self-renewal, survival, and tumorigenesis in vivo.

Main Methods:

• Cell viability, proliferation, and colony formation assays (MTS, colony formation assay).
• Transwell migration assays, flow cytometry for cell cycle and apoptosis analysis.
• In vivo tumor growth assays, sphere formation assays, Western Blot, and qRT-PCR for stemness marker analysis.

Main Results:

• Napabucasin treatment reduced prostate cancer cell viability, colony formation, migration, and survival.
• Napabucasin induced cell cycle arrest and increased sensitivity to docetaxel in vitro.
• Napabucasin significantly inhibited PrCSC spherogenesis, reduced their survival, and repressed in vivo tumorigenesis, with downregulated stemness markers.

Conclusions:

• Napabucasin demonstrates potent anti-cancer activity against prostate cancer stem cells (PrCSCs).
• Napabucasin shows potential as a therapeutic agent for advanced prostate cancer, particularly castration-resistant prostate cancer (CRPC).
• Napabucasin represents a novel therapeutic strategy targeting stemness pathways in prostate cancer.